SCHEMBL14200087

SCHEMBL14200087

CC(=O)OC[C@@H](N)Cc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
ALPI P09923 1/20 0.55
PKM P14618 1/20 0.55
PTGS1 P23219 1/20 0.55
XIAP P98170 1/20 0.55
SLC7A5 Q01650 1/20 0.55
EPHX1 P07099 1/20 0.53
MMP2 P08253 3/20 0.51
SCN4A P35499 2/20 0.51
TACR1 P25103 1/20 0.49
SLC15A1 P46059 1/20 0.47
ANPEP P15144 1/20 0.47
SRR Q9GZT4 1/20 0.46
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46
MAOA P21397 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12691524 1.00 ALDH1A1 (0.55) ALDH1A1ALPIPKMPTGS1XIAP
SCHEMBL10905702 1.00 ALDH1A1 (0.55) ALDH1A1ALPIPKMPTGS1XIAP
Solriamfetol SCHEMBL30518840 0.87 PKM (0.51) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL24453058 0.86 EPHX1 (0.57) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL12019787 0.85 ALDH1A1 (0.50) ALDH1A1ALPIPKMPTGS1XIAP
Solriamfetol SCHEMBL30929349 0.84 PKM (0.56) ALPIPKMPTGS1XIAPSLC7A5
Solriamfetol SCHEMBL42526 0.84 PKM (0.56) ALPIPKMPTGS1XIAPSLC7A5
Solriamfetol SCHEMBL42525 0.84 PKM (0.56) ALPIPKMPTGS1XIAPSLC7A5
Solriamfetol SCHEMBL30929348 0.84 PKM (0.56) ALPIPKMPTGS1XIAPSLC7A5
Solriamfetol SCHEMBL2739637 0.84 PKM (0.56) ALPIPKMPTGS1XIAPSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115650875-A Dichondra repens element derivative and preparation method and application thereof 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2023-01-31 CN disclosed
US-20170355668-A1 METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER SK BIOPHARMACEUTICALS CO LTD (KR) 2017-12-14 US disclosed
US-20080090902-A1 PHENYLALKYLAMINO CARBAMATE COMPOSITIONS JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090902-A1 PHENYLALKYLAMINO CARBAMATE COMPOSITIONS CA2, PKD1, CA4 ALDH1A1 3441/4885ALPI 339/4885PKM 2121/4885
US-20170355668-A1 METHODS FOR TREATING ATTENTION-DEFICIT/HYPERACTIVITY DISORDER CHAT, SLC6A3, SLC6A2 ALDH1A1 325/4885ALPI 1614/4885PKM 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.